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It has been an absolute pleasure to be the guest editor of this Special Issue! As the
title indicates, the topic is on the advances made against cancer. Sixteen manuscripts were
published, including eleven research papers and five reviews. The depth and width of
the research presented is truly impressive, i.e., the detail of the biological processes within
the cancer cells that are elucidated and the diverse nature of the chemical matter under
investigation, spanning from heavy metals to small organic molecules.
New synthesized anticancer compounds were introduced in the s-triazine Schiff base
derivatives against human breast carcinoma (MCF-7) and colon cancer (HCT-116) cell
lines [1], the thioureas chelated with Ru, Os, Rh and Ir as shown in Figure 1 [2], 3-carene
derivatives as novel inhibitors of tyrosyl-DNA phosphodiesterase 1 (TDP1), a promising
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Figure 1. The molecular structure of one of the chelated thiourea enantiomers found (left) and Ir
distribution in SKOV-3 cancer cells after treatment as determined by X-ray fluorescence microscopy
(right) [2].
The biological mechanism of action was further elucidated for known and new bioac-
tive compounds; 10-gingerol was shown to target lipid rafts in triple negative breast cancer
cells [5], a new barbituric acid derivative has antiproliferative and antimigratory effects in
hepatocellu ar carcinoma [6], pyrimethamine, an established antiparasiti drug, was identi-
fied in a screen of known drugs against exon 2-depleted splice variant of aminoacyl-tRNA
synthetase-interacting multifunctional protein 2, and was effective in mouse xenografts,
making it a promising repositioned drug [7], the flavonoid quercetin was tested with
docetaxel as a potential adjuvant therapy for breast cancer [8], the immunomodulating
drugs thalidomide, lenalidomide, and pomalidomide were tested on cultured normal
monocytes, cancer-supporting stromal cells, altering their metabolism and cell–cell commu-
nication [9], another flavonoid kushenol Z, isolated from the roots of Sophora flavescens used
in Traditional Chinese Medicine (TCM), inhibited proliferation and induced apoptosis in
non-small-cell lung cancer cells [10], and finally, three new dual inhibitors of tryptophan ca-
tabolizing enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase
(TDO2), valid cancer immunotherapy targets, were established using virtual screening of
natural products [11].
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The review articles were just as varied as the research papers regarding their topics;
tannic acid was reviewed for its anticancer activity and its capacity as a drug delivery
vehicle [12], the effect of the integrin peptide TNIIIA2 acting as a pro-cancer factor and
peptide FNIII14 acting as an anticancer agent was reviewed based on the regulation on
β1-integrin activation, which are matricellular proteins existing in association with the
extracellular matrix [13], the cytotoxic, anti-inflammatory and anticancer effects of C17 and
C18 acetylenic oxylipins from terrestrial plants were presented and potential mechanisms of
action and structural requirements for optimal cytotoxicity were discussed [14], the recent
advances in the chemical synthesis and biological evaluation of nucleoside analogues as
potential anticancer agents were discussed with the focus on the 4′-heteroatom substitution
of the furanose oxygen, 2′-, 3′-, 4′- and 5′-position ring modifications and the development
of new prodrug strategies for these compounds, as shown in Figure 2 [15], and the potential
of metalloorganic chemistry was reviewed for the mechanism of biological activity of
Vanadium complexes, including DNA binding, oxidative stress, cell cycle regulation and
programed cell death [16].
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In conclusion, an impressive array of new potential therapies is presented in this
Special Issue. The number of different approaches to defeat cancer is truly inspiring, giving
one hope for the eventual management and cure of most, if not all, cancer types.
Conflicts of Interest: The author declares no conflict of interest.
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